Altria pays $235 million to settle Juul lawsuits

May.11.2023
Altria pays $235 million to settle Juul lawsuits
Altria Group has agreed to pay $235 million to settle lawsuits related to its investment in Juul and youth vaping.

On May 10th, according to a report from Reuters, Altria Group announced it will pay $235 million to settle at least 6,000 lawsuits accusing the company of encouraging teenage e-cigarette use by investing in Juul, a leading e-cigarette manufacturer.


This deal settled nearly all lawsuits brought against Altria by local government agencies and individuals across the United States related to Juul. Altria anticipates recording a pre-tax charge of $235 million in the second quarter of 2023 and intends to exclude this charge from adjusted earnings per share.


Sarah London, one of the lead lawyers for the plaintiff, stated in a written statement regarding the settlement that it would provide "unprecedented and truly meaningful relief for youth, parents, and government organizations nationwide.


Murray Garnick, Altria's Executive Vice President and General Counsel, recently said that the claims against Altria are unfounded. However, he believes that settling the matter would be in the best interest of the company's shareholders.


However, we believe this resolution avoids the uncertainty and costs of lengthy legal proceedings, and is in the best interests of our shareholders.


The plaintiff in the lawsuit alleges that Juul employed inappropriate methods (such as promoting flavored e-cigarettes and utilizing internet and social media campaigns) to market their products to minors, and that Altria assisted Juul's marketing efforts by allowing them to use their sales team and display their products on shelves next to Altria's own products.


Altria has announced that it has relinquished its 35% stake in Juul. As of December 2022, its stake in Juul was worth $250 million, down from the $12.8 billion it invested in 2018.


Juul has reached settlements in the majority of its cases, paying over $1 billion to 48 states and territories, as well as $1.7 billion to individual and local government entities.


Beth Wilkinson, lawyer for Altria, stated in a recent lawsuit that the company did not benefit from its investment in JUUL.


This investment of 12.8 billion dollars did not result in any returns, and Altria did not benefit from it in any way.


References:


Altria has agreed to pay $235 million in order to settle all cases related to Juul, the vaping giant in which the cigarette maker has a 35% stake. This settlement will end all lawsuits that have been filed against Altria over Juul-related issues.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

FDA Says Flavored ENDS Must Show “Added Benefit” as Small Manufacturers Seek Clearer Switching Benchmarks
FDA Says Flavored ENDS Must Show “Added Benefit” as Small Manufacturers Seek Clearer Switching Benchmarks
During the FDA PMTA roundtable session on “Studies of Adult Benefit,” officials said flavored ENDS must demonstrate “added benefit” over tobacco-flavored products under the APPH standard, including sustained complete switching evidence. Small manufacturers questioned switching benchmarks, study duration, and bridging expectations.
Feb.11
Special Report|Russia scales back anti-vaping drive, limits ban to single-region trial
Special Report|Russia scales back anti-vaping drive, limits ban to single-region trial
After months of debate, Russian lawmakers have retreated from plans for a nationwide vaping ban, opting instead for a single-region pilot. The shift reflects pressure from business groups and fiscal authorities, amid warnings that sweeping prohibitions could fuel illegal trade while undermining efforts to regulate the market.
Jan.22
Indiana SB 185 Advances: Foreign-Made Vapes Would Be Barred, With Focus on China
Indiana SB 185 Advances: Foreign-Made Vapes Would Be Barred, With Focus on China
Indiana State Sen. Ron Alting is backing Senate Bill 185, which would ban vape shops in Indiana from selling any foreign-made vaping products and restrict retail shelves to U.S.-made items. Alting has framed the proposal as a consumer-safety measure and has singled out China, citing industry reporting that China produces more than 90% of the world’s vape hardware.
Jan.27 by 2FIRSTS.ai
Product | 5ml/2ml Dual Versions, Up to 45W Output: VAPORESSO Launches LUXE X3 on Official Website
Product | 5ml/2ml Dual Versions, Up to 45W Output: VAPORESSO Launches LUXE X3 on Official Website
VAPORESSO has listed the LUXE X3, a new addition to its LUXE X series, on its official website. The device features a 2,600mAh built-in battery, adjustable 5–45W output and a 0.8-inch digital display, and comes with a 5ml pod (2ml for the TPD version). The LUXE X3 has also appeared on some UK and US online retailers for pre-order, with prices below the company’s stated MSRP of $37.9.
Jan.19 by 2FIRSTS.ai
2Firsts Interview with Glas |Why a California ENDS Company Believes Its Age-gated Flavored Vape Could Be Next in Line for FDA Authorization
2Firsts Interview with Glas |Why a California ENDS Company Believes Its Age-gated Flavored Vape Could Be Next in Line for FDA Authorization
As the FDA advances efforts to streamline its PMTA review process, including support for small businesses, expectations are rising that additional product authorizations may follow. Age-verification technology is emerging as a key consideration in future approvals.In this interview, California-based Glas discusses its G2 platform, integrating smartphone-based identity verification, proximity controls and anti-counterfeit systems, and outlines its positioning under the FDA’s PMTA framework.
Mar.02
Rethinking Nicotine Harm Reduction: A Neuroscientist’s Perspective on Scientific Gaps and Future Directions — By Dr. Xin-an Liu
Rethinking Nicotine Harm Reduction: A Neuroscientist’s Perspective on Scientific Gaps and Future Directions — By Dr. Xin-an Liu
After France’s ANSES report on nicotine products and harm reduction, Dr. Xin-an Liu wrote to 2Firsts reassessing the field’s foundations. She argues the debate reveals gaps in evidence on long-term behavioral substitution, addiction pathways and neurobiological impacts, and calls for longitudinal research, integrated behavioral science and neuroimaging, clearer risk assessment and stronger transparency to ensure policy and next-generation product development rest on solid evidence.
Industry Insight
Feb.24